The utility of antifungal agents for asthma

Current Opinion in Pulmonary Medicine

Volumn 16, Issue 1, 2010, Pages 36-41

  Gore, Robin B ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b LANCASHIRE TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Aspergillus fumigatus; Asthma; Azoles; Fungus; Itraconazole

Indexed keywords

ANTIFUNGAL AGENT; BECLOMETASONE; BUDESONIDE; CICLESONIDE; CORTICOSTEROID; FLUCONAZOLE; FLUTICASONE; ITRACONAZOLE; KETOCONAZOLE; NATAMYCIN;

ANTIFUNGAL SUSCEPTIBILITY; ASTHMA; CLINICAL TRIAL; CUSHINGOID SYNDROME; DISEASE SEVERITY; DRUG INHIBITION; FUNGAL COLONIZATION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LUNG ASPERGILLOSIS; QUALITY OF LIFE; RESPIRATORY TRACT INFECTION; REVIEW; TREATMENT DURATION;

ANTIFUNGAL AGENTS; ASTHMA; FUNGI; HUMANS; RESPIRATORY SYSTEM; SEVERITY OF ILLNESS INDEX;

EID: 74549175386     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e328333900a     Document Type: Review

References (66)

1. Denning DW, O'Driscoll BR, Powell G, et al. Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: The Fungal Asthma Sensitization Trial (FAST) study. Am J Respir Crit Care Med 2009; 179:11-18.
2. Platts-Mills TA, Vervloet D, Thomas WR, et al. Indoor allergens and asthma: report of the Third International Workshop. J Allergy Clin Immunol 1997; 100:S2-S24. (Pubitemid 128717763)
3. Tovey ER, Almqvist C, Li Q, et al. Nonlinear relationship of mite allergen exposure to mite sensitization and asthma in a birth cohort. J Allergy Clin Immunol 2008; 122:114-118.
4. Gore RB, Curbishley L, Truman N, et al. Intranasal air sampling in homes: relationships among reservoir allergen concentrations and asthma severity. J Allergy Clin Immunol 2006; 117:649-655.
5. Langley SJ, Goldthorpe S, Craven M, et al. Exposure and sensitization to indoor allergens: association with lung function, bronchial reactivity, and exhaled nitric oxide measures in asthma. J Allergy Clin Immunol 2003; 112:362-368.
6. Arshad SH, Hamilton RG, Adkinson NF Jr. Repeated aerosol exposure to small doses of allergen. A model for chronic allergic asthma. Am J Respir Crit Care Med 1998; 157:1900-1906.
7. Hawksworth DL, Rossman AY. Where are all the undescribed fungi? Phytopathology 1997; 87:888-891.
8. Horner WE, Helbing A, Salvaggio JE, et al. Fungal allergens. Clin Microbiol Rev 1995; 2:161-179.
9. Bowyer P, Denning DW. Genomic analysis of allergen genes in Aspergillus spp.: the relevance of genomics to everyday research. Med Mycol 2007; 45:17-26.
10. Crameri R, Zeller S, Glaser AG, et al. Cross-reactivity among fungal allergens: a clinically relevant phenomenon? Mycoses 2009; 52:99-106.
11. Zeller S, Rhyner C, Meyer N, et al. Exploring the repertoire of IgE-binding selfantigens associated with atopic eczema. J Allergy Clin Immunol 2009; 124:278-285.
12. Mari A, Schneider P, Wally V, et al. Sensitization to fungi: epidemiology, comparative skin tests, and IgE reactivity of fungal extracts. Clin Exp Allergy 2003; 33:1429-1438.
13. Fisk WJ, Lei-Gomez Q, Mendell MJ. Meta-analyses of the associations of respiratory health effects with dampness and mold in homes. Indoor Air 2007; 17:284-296.
14. Mendell MJ, Mirer AG, Cheung K, et al. Health effects associated with dampness and mould. In: Heseltine E, Rosen J, editors. WHO guidelines for indoor air quality: Dampness and Mould. Copenhagen, Denmark: WHO Regional Office for Europe; 2009. pp. 63-92.
15. Aimanianda V, Bayry J, Bozza S, et al. Surface hydrophobin prevents immune recognition of airborne fungal spores. Nature 2009; 460:1117-1121.
16. Malling H-J. Diagnosis and immunotherapy of mould allergy IV. Relation between asthma symptoms, spore counts and diagnostic tests. Allergy 1986; 41:342-350.
17. Virnig C, Busk RK. Allergic bronchopulmonary aspergillosis: a US perspective. Curr Opin Pulm Med 2007; 13:67-71.
18. Knutsen AP, Mueller KR, Levine AD, et al. Asp f I CD4+ TH2-like T-cell lines in allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 1994; 94:215-221.
19. Denning DW, O'Driscoll BR, Hogaboam CM, et al. The link between fungi and severe asthma: a summary of the evidence. Eur Respir J 2006; 27:615-626.
20. O'Driscoll BR, Powell G, Chew F, et al. Comparison of skin prick tests with specific serum immunoglobulin E in the diagnosis of fungal sensitization in patients with severe asthma. Clin Exp Allergy 2009; 39:1677-1683.
21. Arshad SH, Tariq SM, Matthews S, Hakim E. Sensitization to common allergens and its association with allergic disorders at age 4 years: a whole population birth cohort study. Pediatrics 2001; 108:E33.
22. Peat JK, Tovey E, Mellis CM, et al. Importance of house dust mite and Alternaria allergens in childhood asthma: an epidemiological study in two climatic regions of Australia. Clin Exp Allergy 1993; 23:812-820.
23. O'Driscoll BR, Hopkinson LC, Denning DW. Mold sensitization is common amongst patients with severe asthma requiring multiple hospital admissions. BMC Pulm Med 2005; 5:4.
24. Zureik M, Neukirch C, Leynaert B, et al. Sensitization to airborne moulds and severity of asthma: cross sectional study from European Community respiratory health survey. Br Med J 2002; 325:411-414.
25. Atkinson RW, Strachan DP, Anderson HR, et al. Temporal associations between daily counts of fungal spores and asthma exacerbations. Occup Environ Med 2006; 63:580-590.
26. Newson R, Strachan D, Corden J, Millington W. Fungal and other spore counts as predictors of admissions for asthma in the Trent region. Occup Environ Med 2000; 57:786-792.
27. Rosas I, McCartney HA, Payne RW, et al. Analysis of the relationships between environmental factors (aeroallergens, air pollution, and weather) and asthma emergency admissions to a hospital in Mexico City. Allergy 1998; 53:394-401.
28. O'Hollaren MT, Yunginger JW, Offord KP, et al. Exposure to an aeroallergen as a possible precipitating factor in respiratory arrest in young patients with asthma. New Engl J Med 1991; 324:359-363.
29. Delfino RJ, Zeiger RS, Seltzer JM, et al. The effect of outdoor fungal spore concentrations on daily asthma severity. Environ Health Perspect 1997; 105:622-635.
30. Pulimood TB, Corden JM, Bryden C, et al. Epidemic asthma and the role of the fungal mold Alternaria alternata. J Allergy Clin Immunol 2007; 120:610-617.
31. Quirce S, Cuevas M, Díez-Gómez M, et al. Respiratory allergy to Aspergillusderived enzymes in bakers' asthma. J Allergy Clin Immunol 1992; 90:970-978.
32. Matheson MC, Abramson MJ, Dharmage SC, et al. Changes in indoor allergen and fungal levels predict changes in asthma activity among young adults. Clin Exp All 2005; 35:907-913.
33. Taskinen T, Hyvärinen A, Meklin T, et al. Asthma and respiratory infections in school children with special reference to moisture and mold problems in the school. Acta Paediatr 1999; 88:1373-1379.
34. Salo PM, Arbes SJ Jr, Sever M, et al. Exposure to Alternaria alternata in US homes is associated with asthma symptoms. J Allergy Clin Immunol 2006; 118:892-898.
35. Woodcock AA, Steel N, Moore CB, et al. Fungal contamination of bedding. Allergy 2006; 61:140-142.
36. Green BJ, Sercombe JK, Tovey ER. Fungal fragments and undocumented conidia function as new aeroallergen sources. J Allergy Clin Immunol 2005; 115:1043-1048.
37. Bohn JA, BeMiller JN. (1!3)-b-D-glucans as biological response modifiers: a review of structure-functional activity relationships. Carbohydrate Polymers 1995; 28:3-14
38. Sercombe JK, Eduard W, Romeo TC, et al. Detection of allergens from Alternaria alternata by gold-conjugated antihuman IgE and field emission scanning electron microscopy. J Immunol Methods 2006; 316:167-170.
39. Halstensen AS, Nordby KC, Wouters IM, Eduard W. Determinants of microbial exposure in grain farming. Ann Occup Hyg 2007; 51:581-592.
40. Lass-Flörl C, Salzer GM, Schmid T, et al. Pulmonary Aspergillus colonization in humans and its impact on management of critically ill patients. Br J Haem 1999; 104:745-747.
41. Sellart-Altisent M, Torres-Rodríguez JM, Gómez de Ana S, Alvarado-Ramírez E. Nasal fungal microbiota in allergic and healthy subjects. Rev Iberoam Micol 2007; 24:125-130.
42. Ando N, Takatori K. Fungal flora of the conjunctival sac. Am J Ophthalmol 1982; 94:67-74.
43. Okudaira M, Kurata H, Sakabe F. Studies on the fungal flora in the lung of human necropsy cases. A critical survey in connection with the pathogenesis of opportunistic fungus infections. Mycopathologia 1977; 61:3-18.
44. Syhre M, Scotter JM, Chambers ST. Investigation into the production of 2-Pentylfuran by Aspergillus fumigatus and other respiratory pathogens in vitro and human breath samples. Med Mycol 2008; 46:209-215.
45. Fredricks DN, Fiedler TL, Marrazzo JM. Molecular identification of bacteria associated with bacterial vaginosis. N Engl J Med 2005; 353:1899-1911.
46. Shale DJ, Faux JA, Lane DJ. Trial of ketoconazole in noninvasive pulmonary aspergillosis. Thorax 1987; 42:26-31.
47. Currie DC, Lueck C, Milburn HJ, et al. Controlled trial of natamycin in the treatment of allergic bronchopulmonary aspergillosis. Thorax 1990; 45:447-450.
48. Stevens DA, Schwartz HJ, Lee JY, et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med 2000; 342:756-762.
49. Wark PA, Hensley MJ, Saltos N, et al. Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomized controlled trial. J Allergy Clin Immunol 2003; 111:952-957.
50. Ward GW Jr, Woodfolk JA, Hayden ML, et al. Treatment of late-onset asthma with fluconazole. J Allergy Clin Immunol 1999; 104:541-546.
51. Wark P, Gibson PG, Wilson A. Azoles for allergic bronchopulmonary aspergillosis associated with asthma. Cochrane Database Syst Rev 2004; CD001108. doi: 10.1002/14651858.CD001108.pub2.
52. Todd GR, Acerini CL, Ross-Russell R, et al. Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Arch Dis Child 2002; 87:457-461.
53. Molimard M, Girodet PO, Pollet C, et al. Inhaled corticosteroids and adrenal insufficiency: prevalence and clinical presentation. Drug Saf 2008; 31:769-774.
54. Mortimer KJ, Tata LJ, Smith CJ, et al. Oral and inhaled corticosteroids and adrenal insufficiency: a case-control study. Thorax 2006; 61:405-408.
55. Woods DR, Arun CS, Corris PA, Perros P. Cushing's syndrome without excess cortisol. Br Med J 2006; 332:469-470.
56. Varis T, Kivisto KT, Neuvonen PJ. The effects of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone. Eur J Clin Pharmacol 2000; 56:57-60.
57. Varis T, Kivisto KT, Neuvonen PJ. The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal suppressant effect. Clin Pharmacol Ther 2000; 68:487-494.
58. Pearce RE, Leeder JS, Kearns GL. Biotransformation of fluticasone: in vitro characterization. Drug Metab Dispos 2006; 34:1035-1040.
59. Jönsson G, Aström A, Andersson P. Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver. Drug Metab Dispos 1995; 23:137-142.
60. Foisy MM, Yakiwchuk EM, Chiu I, Singh AE. Adrenal suppression and Cushing's syndrome secondary to an interaction between ritonavir and fluticasone: a review of the literature. HIV Med 2008; 9:389-396.
61. Daveluy A, Raignoux C, Miremont-Salamé G, et al. Drug interactions between inhaled corticosteroids and enzymatic inhibitors. Eur J Clin Pharmacol 2009; 65:743-745.
62. De Wachter E, Malfroot A, De Schutter I, et al. Inhaled budesonide induced Cushing's syndrome in cystic fibrosis patients, due to drug inhibition of cytochrome P450. J Cyst Fibros 2003; 2:72-75.
63. Naef R, Schmid C, Hofer M, et al. Itraconazole comedication increases systemic levels of inhaled fluticasone in lung transplant recipients. Respiration 2007; 74:418-422.
64. Rohatagi S, Luo Y, Shen L, et al. Protein binding and its potential for eliciting minimal systemic side effects with a novel inhaled corticosteroid, ciclesonide. Am J Ther 2005; 12:201-209.
65. Szefler S, Rohatagi S, Williams J, et al. Ciclesonide, a novel inhaled steroid, does not affect hypothalamic-pituitary-adrenal axis function in patients with moderate-to-severe persistent asthma. Chest 2005; 128:1104-1114.
66. Kaliner MA. Pharmacologic characteristics and adrenal suppression with newer inhaled corticosteroids: a comparison of ciclesonide and fluticasone propionate. Clin Ther 2006; 28:319-331.